Rubraca is a poly (ADP-ribose) polymerase (PARP) inhibitor approved for the treatment of certain cancers associated with BRCA mutations. It works by targeting the DNA repair mechanisms of cancer cells, thereby inhibiting their ability to repair damaged DNA, leading to cell death, particularly in tumor cells. This drug is specifically indicated for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer with deleterious BRCA mutations who have responded to prior platinum-based chemotherapy.

In addition to ovarian cancer, Rubraca has potential indications for prostate cancer treatment, though details regarding its use in this context are not explicitly mentioned in the provided specification. The primary therapeutic benefit lies in its ability to exploit synthetic lethality in tumor cells, making it a critical treatment option for patients with specific genetic profiles, particularly those with BRCA mutations.